Cogent Biosciences (COGT) vs PTC Therapeutics (PTCT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Cogent Biosciences (COGT) has outperformed PTC Therapeutics (PTCT) over the past year, gaining 95.2% versus a loss of 1.1%. Over five years, COGT leads with a +226.2% price change compared with +66.0% for PTCT. PTC Therapeutics is the larger company by market cap ($5.20 billion vs $5.09 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | COGT | PTCT |
|---|---|---|
| Share price | $29.34 | $62.35 |
| Market cap | $5.09B | $5.20B |
| 1-day change | -2.65% | -1.39% |
| YTD return | -15.15% | -16.76% |
| 1-year return | +95.21% | -1.06% |
| 5-year return | +226.19% | +66.00% |
| Forward P/E | — | 23.29 |
| EPS (TTM) | $-2.16 | $-0.65 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $1.73B |
| Revenue growth (YoY) | — | +114.51% |
| Net income (latest FY) | $-328.94M | $682.64M |
| Operating margin | — | 50.09% |
| Net margin | — | 39.44% |
| 52-week high | $43.73 | $90.87 |
| 52-week low | $13.78 | $61.23 |
| Distance from 52-week high | -32.91% | -31.39% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +90.25% | +63.26% |
| Average volume | 1.90M | 1.14M |
| Shares outstanding | 173.52M | 83.46M |
| Employees | 258 | 991 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- COGT has outperformed PTCT by 96.3 percentage points over the past year.
About Cogent Biosciences
COGT stock →Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 258 employees
About PTC Therapeutics
PTCT stock →PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.
Health Care · Biotechnology: Pharmaceutical Preparations · 991 employees
COGT vs PTCT FAQ
Which is bigger, Cogent Biosciences or PTC Therapeutics?
PTC Therapeutics (PTCT) is larger, with a market capitalization of $5.20B compared with $5.09B for Cogent Biosciences (COGT).
Which stock has performed better over the past year, COGT or PTCT?
COGT returned +95.21% over the past 12 months, compared with -1.06% for PTCT (price return, excluding dividends). Past performance does not predict future results.
Are Cogent Biosciences and PTC Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.